DBV Technologies SA是一家法国的临床阶段生物制药公司,致力于通过开发名为Vaskin的技术平台来改变免疫疗法的业务。该公司的治疗方法基于表皮免疫疗法,即EPIT,它是使用Viaskin通过完整皮肤向免疫系统提供生物活性化合物的专有方法。该公司致力于治疗患有严重食物过敏的患者,包括婴儿和儿童,对这些患者来说,安全性至关重要,因为将不良过敏原引入血液中会导致严重或危及生命的过敏反应,例如过敏性休克。该公司用于过敏治疗的产品包括Viaskin花生、Viaskin牛奶和Viaskin鸡蛋。该公司在美国运营着一家子公司DBV Technologies Inc。
名称 | 标题 | 任期 | 年龄 |
|---|---|---|---|
| Michel de Rosen | Independent Chairman of the Board | 2019 | 75 |
| Daniel Tassé | CEO & Director | 2019 | 66 |
| Hugh A. Sampson | Scientific Adviser to the CEO & Chairman of Scientific Advisory Board | 2020 | 77 |
| Michael J. Goller | Director | 2015 | 51 |
| Julie O'Neill | Director | 2017 | 60 |
| Timothy E. Morris | Independent Director | 2021 | 65 |
| Paul-Henri Lambert | Member of the Scientific Advisory Board | - | 87 |
| Mailys Ferrere | Director | 2016 | 64 |
| Jean-François Nicolas | Member of Scientific Advisory Board | 2019 | - |
| Emma Guttman-Yassky | Member of Scientific Advisory Board | 2019 | - |
| Jim Krueger | Member of Scientific Advisory Board | 2019 | - |
| Miriam Merad | Member of Scientific Advisory Board | 2019 | - |
| Adora Ndu | Independent Director | 2021 | 45 |
| Ravi Madduri Rao | Independent Director | 2021 | 59 |
| Betty A. Diamond | Member of Scientific Advisory Board | 2021 | - |
| Daniele Guyot-Caparros | Independent Director | 2022 | 68 |
| Philina Lee | Independent Director | 2025 | 49 |